Kringle Pharma is a late clinical-stage biopharmaceutical company.
Currently, we are conducting clinical trials of HGF protein, which is a regenerative drug candidate, for the treatment of rare and intractable diseases.
Our strength is that we have a proprietary platform for manufacturing HGF protein in pharmaceutical grade. While maintaining the basic policy of in-house development and sales model, we will build a unique business model that combines out-licensing, co-development and API supply models to maximize profits over the medium to long term.